Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV).

Trial Profile

Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Arterial occlusive disorders; Coronary artery disease; Restenosis
  • Focus Therapeutic Use
  • Acronyms PRISON-IV
  • Most Recent Events

    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Nov 2015 Planned End Date changed from 1 May 2018 to 1 May 2020 as reported by ClinicalTrials.gov record.
    • 01 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top